Syros Pharmaceuticals sets terms for upcoming U.S. IPO
June 21, 2016
Syros Pharmaceuticals plans to list common stock on the NASDAQ under the symbol SYRS. The gene-repression and disease-prevention company will reportedly offer four million shares and price its IPO between $14 and $16 per share; a midpoint offering would raise $60 million. Syros Pharmaceuticals has raised capital from firms including Flagship Ventures (23.8% pre-IPO stake), ARCH Venture Partners (22.9%) and Fidelity (11.4%). The company's most recent VC round raised $40 million at a valuation of $195 million in January.